NDA 021636 · Salix
Zegerid
Omeprazole, Sodium Bicarbonate · Oral · Proton Pump Inhibitor
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Jun 15, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
988
158 Phase 3, 48 recruiting
FAERS reports
2,739
1,742 serious, 167 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 19, 2023.
ZEGERID for oral suspension and ZEGERID capsules are indicated in adults for the : • short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. • short-term treatment (4 to 8 weeks) of active benign gastric ulcer. • treatment of heartburn and other symptoms associated with GERD for up to 4 weeks. • short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD which has been diagnosed by endoscopy in adults. o The efficacy of ZEGERID used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8-week courses of ZEGERID may be considered. • maintenance of healing of EE due to acid-mediated GERD. Controlled studies do not extend beyond 12 months. ZEGERID for oral suspension is indicated in adults for the : • reduction of risk of upper GI bleeding in critically ill adult patients. ZEGERID is a proton pump inhibitor (PPI). ZEGERID for oral suspension and ZEGERID capsules are indicated in adults for: • Treatment of active duodenal ulcer ( 1 ) • Treatment of active benign gastric ulcer ( 1 ) • Treatment of erosive esophagitis (EE) due to acid-mediated gastroesophageal reflux disease (GERD) ( 1 ) • Maintenance of healing of EE ( 1 ) ZEGERID for oral suspension is indicated in adults for: • Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill patients ( 1 )
Mechanism: Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 15, 2004 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination ReviewOther Important Information from FDALabel
2 products under this application
- ZEGERID · OMEPRAZOLE 20MG/PACKET; SODIUM BICARBONATE 1.68GM/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · FOR SUSPENSION, ORAL · Discontinued · TE AB
- ZEGERID · OMEPRAZOLE 40MG/PACKET; SODIUM BICARBONATE 1.68GM/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · FOR SUSPENSION, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Omeprazole" as an intervention, any sponsor and status, largest first.
- Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)Pivotal-lookingTerminated
Cogentus PharmaceuticalsIndustry
NCT00557921 · 5,000 participants (planned) · Start Dec 2007 · Primary completion Nov 2009
Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Plavix (clopidogrel 75 mg) and aspirin · For: Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease and 1 more
Sites: Alexander City, Alabama; Birmingham, Alabama; Geneva, Alabama · 491 sites in all
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06943794 · 4,824 participants (planned) · Start Mar 30, 2026 · Primary completion May 1, 2030
Drug: recommendations for Hp eradication treatment · For: Gastric (Stomach) Cancer
Sites: Tongling, China
- Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With ArthritisPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00141102 · 4,484 participants · Start Oct 2005 · Primary completion May 2009
Drug: Celecoxib; Diclofenac + Omeprazole · For: Osteoarthritis; Arthritis, Rheumatoid
Sites: Genk, Belgium; Ghent, Belgium; Hasselt, Belgium · 194 sites in all
- A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong ProvincePivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00339768 · 3,411 participants · Start Jul 1, 1995 · Primary completion Jun 10, 1996
Drug: Amoxicillin/omeprazole · For: Precancerous Gastric Lesions
Sites: Beijing, China
- Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD PatientsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00444275 · 3,029 participants · Start Mar 2007 · Primary completion Oct 2008
Drug: esomeprazole (Nexium®); Xolaam® · For: GERD
Sites: Rouen, France
- A Multi-center Study for Individual Treatment of Helicobacter Pylori InfectionPivotal-lookingStatus unknown
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT02689583 · 3,000 participants (planned) · Start Mar 2016 · Primary completion Mar 2017
Drug: Antibiotic selection based on the antibiotic susceptibility testing · For: Gastritis; Gastric Ulcer
- Helicobacter Pylori Eradication to Prevent Gastric CancerPivotal-lookingActive, not recruiting
Jie-Jun WangAcademic, hospital or other
NCT01133951 · 3,000 participants · Start Jun 2010 · Primary completion Jan 2012
Drug: OAC triple therapy; Placebo · For: Helicobacter Infections; Stomach Neoplasms
Sites: Yangzhong, China
- A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's MetaplasiaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00357682 · 2,557 participants · Start Mar 10, 2005 · Primary completion May 31, 2017
Drug: Esomeprazole; Esomeprazole and 1 more · For: Esophageal Cancer; Precancerous Condition
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease788
- acute kidney injury456
- renal failure431
- end stage renal disease212
- drug ineffective200
- renal injury195
- nausea167
- gastrooesophageal reflux disease156
- pain135
- headache131
- fatigue126
- diarrhoea109
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 7 |
| 2006 | 14 |
| 2007 | 26 |
| 2008 | 62 |
| 2009 | 86 |
| 2010 | 119 |
| 2011 | 145 |
| 2012 | 142 |
| 2013 | 102 |
| 2014 | 97 |
| 2015 | 148 |
| 2016 | 150 |
| 2017 | 172 |
| 2018 | 301 |
| 2019 | 513 |
| 2020 | 187 |
| 2021 | 153 |
| 2022 | 101 |
| 2023 | 45 |
| 2024 | 72 |
| 2025 | 58 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zegerid (Omeprazole/Sodium Bicarbonate)
2024 spending
$3.3M
Beneficiaries
252
667 claims
Per beneficiary
$12,949
$105.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,698,746 |
| 2021 | $7,954,260 |
| 2022 | $8,461,055 |
| 2023 | $8,514,993 |
| 2024 | $3,263,247 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q, Wang R, Liu L, et al. · Int J Clin Pharmacol Ther 2015 · Comparative Study, Meta-Analysis
- Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Richter JE, Kahrilas PJ, Johanson J, et al. · Am J Gastroenterol 2001 · Clinical Trial, Comparative Study
- Clopidogrel with or without omeprazole in coronary artery disease.
Bhatt DL, Cryer BL, Contant CF, et al. · N Engl J Med 2010 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Clopidogrel With and Without a Proton Pump Inhibitor: A Systematic Review and Meta-Analysis.
Axelsson MAB, Parodi López N, Wikström Jonsson E, et al. · Basic Clin Pharmacol Toxicol 2025 · Systematic Review, Meta-Analysis
- Curcuma longa Linn versus omeprazole in treatment of functional dyspepsia: A randomized, double-blind, placebo-controlled trial.
Yongwatana K, Harinwan K, Chirapongsathorn S, et al. · J Gastroenterol Hepatol 2022 · Randomized Controlled Trial
- Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
Teng M, Khoo AL, Zhao YJ, et al. · J Clin Pharm Ther 2015 · Comparative Study, Meta-Analysis
Sponsor: Salix
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.